 |
|
anti-EpCAM/anti-CD3 recombinant bispecific monoclonal antibody MT110
A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating and antineoplastic activities. Anti-EpCAM/anti-CD3 recombinant bispecific monoclonal antibody MT110 attaches to both CD3-expressing T lymphocytes and EpCAM-expressing tumor cells, thereby selectively cross-linking tumor and T lymphocytes; this may result in the recruitment of cytotoxic T lymphocytes (CTL) to T lymphocyte/tumor cell aggregates and the CTL-mediated death of EpCAM-expressing tumor cells. CD3 is an antigen expressed on mature T cells; EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | MT110 | | |
|
|
